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Abstract 
Background: Heart failure (HF) with preserved ejection fraction (HFpEF) and monoclonal 
gammopathy of uncertain significance (MGUS) are two entities that share pathophysiological 
mechanisms. The aim herein, was to assess the prevalence of MGUS in patients with HFpEF 
and no left ventricular (LV) hypertrophy, as well as its association with a pre-specified 
clinical endpoint at 12 months. 
Methods: The present study prospectively enrolled 69 patients admitted with HF, with 
ejection fraction ≥ 50%, and LV wall thickness < 12 mm. All patients were screened for 
MGUS. Clinical events were determined over a 12 month follow-up. The pre-specified 
composite clinical endpoint was readmission for heart failure or death. 
Results: The prevalence of MGUS in this population was 13%. There were no differences in 
the incidence of the composite clinical endpoint between patients with and without MGUS. 
Multivariate analysis showed that treatment with angiotensin converting enzyme inhibitors 
(ACEIs) or angiotensin receptor blockers (ARBs) was associated with fewer clinical events 
(HR: 0.153, 95% CI: 0.037–0.622, p = 0.009) and indicated a trend to lower risk of 
readmission for HF and death. Beta-blockers were associated with lower rates of the 
composite clinical endpoint (HR: 0.192, 95% CI: 0.05–0.736, p = 0.016), readmission for HF 
(HR: 0.272, 95% CI: 0.087–0.851, p = 0.025) and indicated a trend to lower mortality. 
Moreover, potassium serum levels > 5 mEq/L were associated with higher rates of the 
composite endpoint (HR: 6.074, 95% CI: 1.6–22.65,p = 0.007). 
Conclusions: The prevalence of MGUS in patients with HFpEF without hypertrophy was 3-
fold that of the general population. There was no significant correlation between clinical 
outcomes and the presence of MGUS. Beta-blockers and ACEIs/ARBs reduced the composite 
of mortality and readmissions for HF in HFpEF patients. Hyperpotassemia was related to 
worse prognosis. 
Key words: monoclonal gammopathy, heart failure, inflammation, ACEI, ARB 
 
 
Introduction 
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Heart failure (HF) is a clinical syndrome characterized by symptoms and signs. HF is 
caused by structural and/or functional cardiac abnormalities, resulting in reduced cardiac 
output and/or elevated intracardiac pressure at rest or during stress [1]. According to 
European guidelines [1] patients present HF with preserved ejection fraction (HFpEF) when 
left ventricular ejection fraction (LVEF) is ≥ 50%, with elevated levels of natriuretic peptides 
(B-type natriuretic peptide [BNP] > 100 pg/mL and/or N-terminal pro-BNP [NT-proBNP] > 
300 pg/mL in the acute setting) and at least one additional criterion, such as relevant structural 
heart disease (left ventricular hypertrophy [LVH] and/or left atrial enlargement) or diastolic 
dysfunction. Recent diagnostic algorithms suggest some functional, morphological and 
biomarker-related criteria for a more accurate diagnosis of HFpEF [2].  
Heart failure affects ≥ 10% of > 70-year old population and up to 50% of all cases of 
HF are believed to be caused by HFpEF [1, 3–5]. Its prevalence has been increasing in recent 
decades, related to the higher percentage of elderly individuals in the population. However, 
epidemiological data are difficult to acquire. One meta-analysis found a mortality rate of 
12.1% during the first year [6]. A new pathophysiological model for HFpEF has been recently 
suggested [5], explaining it as an inflammatory disease. Typically, HFpEF patients are elderly 
with several inflammation-related comorbidities (i.e. diabetes, hypertension), which may 
explain the link between those proinflammatory entities and the presence of HFpEF.  
Monoclonal gammopathies (MGs) are a group of entities associated with the 
proliferation of a single clone of plasma cells. MGs include conditions ranging from 
monoclonal gammopathy of uncertain significance (MGUS), multiple myeloma (MM), 
lymphoplasmacytic lymphoma (LL), and primary amyloidosis (AL) [7,8]. Patients with 
MGUS present monoclonal immunoglobulin concentrations of ≤ 3 g/dL in serum; in the 
absence of lytic bone lesions, anemia, hypercalcemia, and kidney failure related to the 
proliferation of monoclonal plasma cells; and ≤ 10% of plasma cells in the bone marrow [7,8]. 
The prevalence of MGUS is 4.22% among individuals ≥ 60 years of age in the general 
population [8]. Clinical relevance of MGs lies in their high prevalence and underdiagnosis, 
but mainly due to the risk of progression to other entities (16% at 10 years) [8]. All the 
diseases within the MG spectrum may show cardiac involvement, with myocardial deposits of 
paraprotein or its components, that generate a diastolic alteration leading to a restrictive 
pattern and HF [9–13]. MGs trigger a proinflammatory state [14] that could contribute to the 
development of diastolic alterations at a cardiac level. 
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Both HFpEF and MGUS are increasing in prevalence among the older population. 
Given the pathogenesis, both may rely on immune system activation and inflammation 
mechanisms [14, 15], suggesting a possible link between them. 
HFpEF has been described in patients without LV hypertrophic remodeling [16] who 
accomplished other of the definition criteria for HFpEF [1, 2]. Patients with LVH have a high 
incidence of infiltrative diseases [17]. In this study it was sought to select patients without 
significant hypertrophy (< 12 mm), thereby with less probability to present with an infiltrative 
disease and try to establish a correlation between them and the presence of MGUS.  
This study sought to determine whether a correlation exists between HFpEF without 
significant LVH and the presence of MGUS. Based on the epidemiological resemblances and 
a possible inflammatory process underlying both entities, it was hypothesized that MGUS 
could be more prevalent in cases of HFpEF than in the general population. Testing the 
secondary hypothesis, was an inquiry as to whether a correlation exists between the presence 
of MGUS and the clinical outcomes in HFpEF (composite endpoint of rehospitalization for 
HF and mortality, and each component of the combined endpoint). 
 
Methods 
Study design 
This is an observational, prospective, single-center, and prevalence study. Only those 
patients who provided signed written consent were enrolled. The study was approved by 
Fundación Jiménez Díaz Ethics Committee. 
Study population 
Patients were recruited following admission to the Fundación Jiménez Díaz hospital in 
Madrid. All patients had a diagnosis of HFpEF (see inclusion criteria) at the time of 
hospitalization. The hospital database  updated with patient status, test results, scans, and 
assessments from all hospital departments. Furthermore, the online health-care database for 
the entire region of Madrid was searched to determine whether patients had presented to an 
Emergency Department or other service and the exact date of death in cases where the patient 
died.  
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Inclusion criteria 
Inclusion criteria included: 
— age ≥18 years; 
— clinical signs and/or symptoms typical of HF (such as rales and crackles at 
auscultation, pulmonary congestion as seen through chest X-rays, third heart sound), 
BNP > 100 pg/mL or NT-proBNP > 300 pg/mL at hospitalization, in full accordance 
with current guidelines [1];  
— LVEF ≥ 50% at hospitalization (evidenced in a recent echocardiogram at point of care 
or in loco);  
— LV wall thickness < 12 mm at thickest point (recent echocardiogram at point of care 
or in loco). 
 
Exclusion criteria 
All patients that met any of the criteria below were excluded from the study:  
— pre-existing heart condition that may explain HF (i.e. moderate to severe valvular 
disease, prosthetic valve, severe anemia or hyperdynamic circulation, advanced 
second- or third-degree atrioventricular block proven by a pathologic 
electrocardiogram track, etc.); 
— substantial or severe comorbidity that, according to the enroller’s judgement, would 
indicate deteriorated cardiac function; 
— previous or known diagnosis of multiple myeloma, amyloidosis, or 
lymphoplasmacytic lymphoma;  
— autoinflammatory disease or infection that could explain MG. 
 
Enrollment, physical examination, laboratory tests, and imaging 
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Patients who met all inclusion and none of the exclusion criteria provided a written 
statement of consent, in accordance with the requirements of the local ethics committee and in 
adherence of Spanish law.  
Upon enrollment, all patients underwent a whole-body physical examination and the 
following laboratory tests were performed: complete blood count, basic biochemical markers, 
serum proteins, protein electrophoresis test, immunofixation electrophoresis (serum and 
urine) and light chains (serum and urine). As mentioned in inclusion criteria, one of the 
criteria for the diagnosis of HF was BNP > 100 pg/mL or NT-proBNP > 300 pg/mL at 
hospitalization [1]. Moreover, another variable was created, “Elevated natriuretic peptides”, 
that was defined as levels of BNP or NT-proBNP greater than or equal to the median (BNP > 
368 pg/mL or NT-proBNP > 1900 pg/mL). Demographic data, cardiovascular risk factors, 
clinical history, echocardiographic parameters and treatments were recorded. Enlarged left 
atrium (LA) was considered when LA maximum diameter in a parasternal long-axis view was 
≥ 35 mm or when LA major length in an apical four-chamber view was ≥ 53 mm [18]. 
Diastolic function was classified as normal diastolic function, indeterminate or diastolic 
dysfunction [19]. 
When a monoclonal component was found, patients were referred to the Hematology 
Department, where they underwent a complete evaluation and risk stratification. MGUS was 
defined as present monoclonal immunoglobulin concentrations of ≤ 3 g/dL in serum, in the 
absence of lytic bone lesions, anemia, hypercalcemia, and kidney failure related to the 
proliferation of monoclonal plasma cells; and ≤ 10% of plasma cells in the bone marrow [7, 
8].  
At 12 months, the electronic medical records were reviewed for events (hospitalization 
for heart failure and mortality). 
 
Data management and processing 
Two data sheets were used for data collection and analysis:  
— Database #1:  Excel spread sheet containing the pairings (Last name, Name, Medical 
record number), and the study number (randomized number, not related to the patient  
in any way or by its clinical file number, and not generated from the patient’s data). 
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This database was the only one containing the patients’ personal data, and it contained 
no data related to the study or any data related to their health; 
— Database #2: The study number was paired to all of the data retrieved and gathered 
from the patient. This database contained sensible information but when consulted 
alone, patient identification was impossible. 
Once the enrollment process was complete, only the second database was used for the 
purpose of analysis, making the process fully anonymous and non-traceable. 
All data were handled and processed in full accordance with local and European law. 
 
Statistical analysis  
Quantitative variables are displayed as medians (interquartile range). Qualitative 
variables appear as percentages. 
To predict the endpoint at 12 months, a univariate Cox regression analysis for all 
variables was performed. Next, a multivariate analysis was carried out to determine whether 
any of the variables could independently predict major events with the variables with a p 
value in univariate analysis < 0.2. 
The Kaplan-Meier curves and log-rank test were used to compare time to outcome 
according to those variables significantly associated with a higher risk of developing the 
primary outcome. 
Analyses were performed with SPSS 19.0 (SPSS Inc., New York). Statistical tests in 
which p < 0.05 (two-tailed) were considered significant. 
 
Results 
Study population 
Two hundred nine patients admitted with HF to the Fundación Jiménez Díaz were 
preselected between July 17, 2017 and November 11, 2018. One hundred thirty-eight patients 
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were excluded (Fig. 1). Two patients were excluded of the analyses because they didn´t 
undergo blood tests. The final number of patients analyzed was sixty-nine. 
 
Statement of Ethics 
Only patients that signed written consent for the study were enrolled. The study was 
approved by Fundación Jiménez Díaz Ethical Committee. 
 
Baseline characteristics 
The mean age was 83 years, with 46.4% males (Table 1). Atrial fibrillation was 
present in 63.8%. Other cardiovascular risk factors that can indicate underlying inflammatory 
mechanisms were very frequently present, such as diabetes (30.4%), dyslipidemia (56.5%) 
and hypertension (81.2%). Most patients were under loop diuretics (73.9%) and 50.7% were 
receiving angiotensin converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers 
(ARBs). Median BNP was 368 pg/mL and median NT-proBNP was 1900 pg/mL. Natriuretic 
peptides were elevated over the median (BNP > 368 pg/mL, NT-proBNP > 1900 pg/mL) in 
59.6% of patients. Potassium levels were higher than 5 mEq/L at admission in 10.1% of the 
patients. Characteristics by groups (combined endpoint, rehospitalization for heart failure and 
mortality) are presented in Table 1A, B.  
 
Prevalence of MGUS in the HFpEF patient cohort 
The prevalence of MGUS among the patients with HFpEF and LV wall thickness < 12 
mm, was 13% (n = 9) (Table 1A). There were no significant differences in the number of 
patients with or without MGUS by group (Table 1A, B). 
Eight patients had a low risk MGUS and did not need any other complementary test; a 
follow-up was programmed by the Hematology Department in these patients. 1 patient did not  
enter into the study because of death.  
 
Clinical events (combined endpoint, hospitalization for HF, mortality)  
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At 12-month follow-up, 34 (49.2%) patients had met the composite endpoint of 
mortality or rehospitalization for HF. 18 (26%) patients had been readmitted for HF at least 
once and 11 (16%) patients had died (Table 1A, B). In the group with diagnosis of MGUS, 2 
(22%) of patients met the composite clinical endpoint, 1 (11.1%) patient was readmitted for 
HF and 1 (11.1%) patient died; versus 22 (37.5%), 17 (28.3%) and 10 (16.7%), respectively 
in the group without MGUS (Table 2).  
 
Factors influencing the outcome 
The single variable Cox regression was performed for each category of data with 
regard to the composite endpoint, readmission for HF and mortality. A multivariate Cox 
analysis showed that patients taking ACEIs/ARBs were less likely to present the combined 
clinical endpoint (hazard ratio [HR]: 0.153, 95% confidence interval [CI]: 0.037–0.622, p = 
0.009), and had a trend to lower risk of readmission for HF (HR: 0.353, 95% CI: 0.121–1.026, 
p = 0.056) and mortality (HR: 0.275, 95% CI: 0.073–1.041, p = 0.057; Table 3A–C). 
Moreover, patients taking beta-blockers were also less likely to present the combined clinical 
endpoint (HR: 0.192, 95% CI 0.05–0.736, p = 0.016), to be readmitted for HF (HR: 0.272, 
95% CI: 0.087–0.851, p = 0.025) and had a trend to lower risk of death (HR: 0.27, 95% CI: 
0.058–1.249, p = 0.094; Table 3A–C). Besides, patients with potassium serum levels > 5 
mEq/L at admission were more likely to present the combined clinical endpoint (HR: 6.074, 
95% CI: 1.6–22.65, p = 0.007; Table 3A). Patients taking clopidogrel had higher risk of being 
readmitted for HF (HR: 7.938, 95% CI: 1.458–43.227, p = 0.017; Table 3B).  
The Kaplan-Meier curves showed that taking betablockers resulted in lower rates of the 
combined clinical endpoint and readmission for HF, with a trend to lower mortality (Fig. 2A–
C). ARBs/ACEIs were protective in terms of the combined clinical endpoint and had a trend 
to decreased rehospitalization for HF (Fig. 3A, B). Moreover, patients with potassium serum 
levels > 5 mEq/L at admission were more likely to present the combined endpoint when 
compared to those with lower potassium levels (Fig. 4).  
 
Discussion 
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The prevalence of MGUS in patients with HFpEF and LV wall thickness < 12 mm 
was 3 times higher than that in the general population (13% vs. 4.22%). It can therefore be 
deduced that patients with MGUS should be assessed for HF symptoms. In future, MGUS 
may be incorporated into a diagnostic work-up that may include cardiac damage markers, or 
echocardiography [20, 21]. 
For the clinical endpoints, rates of readmission for HF at 12 months was 26%, which 
is lower than previously described, which might be related to the fact that previous studies 
usually include both patients with reduced and preserved ejection fraction [22]. The mortality 
rate of these patients was 16% at 1 year, which was slightly higher than in previous studies 
[22].  
A correlation between outcomes and presence or absence of MGUS could not be 
demonstrated. Since there is no direct proof of cardiotoxicity in MGUS, MGUS may be an 
initial phase (as a first laboratory sign) of protein deposit disease, such as amyloidosis, or 
even progress into multiple myeloma. Even though amyloidosis would drastically change the 
outcome of any patients in the sample presenting the disease, patients were specifically 
selected that had an LV wall thickness < 12 mm, possibly excluding most of the amyloid 
patients, which usually present with LVH. Moreover, the follow-up period in this study was 
far too short for these entities to manifest and consequently alter the outcome of MGUS 
patients.   
ACEIs/ARBs were related to better outcomes in terms of the combined endpoint and 
had a trend to lower rates of readmission for HF and mortality at 12 months. Though patients 
were not categorized by the New York Heart Association/American Heart Association 
functional class, it was deduced from these results that HFpEF patients might benefit from 
ACEIs/ARBs as this therapy approach would downgrade their risk stratum. These results are 
encouraging, especially considering that the most promising drug, sacubitril/valsartan showed 
no benefit when compared to valsartan in the PARAGON-HF, in HFpEF [23]. The use of 
ACEIs/ARB in HFpEF has been previously suggested in a recent meta-analysis [24], although 
single large studies failed to demonstrate this relation [25, 26]. 
The mechanism behind the seemingly protective action of ACEIs/ARBs remains 
unclear, but it may have to do with the pathophysiological mechanism of HF itself. 
Hypertension and cardiac remodeling play a role in the pathogenesis; moreover, the renin–
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angiotensin–aldosterone axis is closely related to inflammation and its byproducts. This 
would justify the rationale behind such an effect, as well as the synergy. The benefits shown 
at short follow-up (Fig. 3A, B) draws attention to the shorter-acting mechanism of cardio-
protection.  
Beta-blockers showed a clear benefit in terms of the combined clinical endpoint, and in 
terms of readmission for heart failure, with a trend to a lower mortality. Previous studies in 
HFpEF patients did not show any significant effect of beta-blockers [27, 28]. However, 
hypotheses have been made about the mechanism of betablockers in HFpEF. Subendocardial 
ischemia is one of the mechanisms that has been suggested in the physiopathology of HFpEF. 
Beta-blockers may improve diastolic filling, enhancing relaxation, and decreasing 
subendocardial ischemia. Other mechanisms such as control of precipitant factors 
(hypertension, tachyarrhythmia) have been suggested for the role of betablockade in HFpEF. 
HFpEF population is very heterogeneous; it affects elderly patients with several 
comorbidities (i.e. diabetes, hypertension) and different cardiac phenotypes (i.e. hypertrophic 
cardiomyopathy, infiltrative disease, hypertensive cardiomyopathy). Moreover, the definition of 
HFpEF has changed over the time, and the current European guidelines [1] define HFpEF when 
LVEF ≥ 50%, and HF with mid-range ejection fraction when LVEF is 40–49%. Some large 
studies have included a very heterogeneous profile of patients; for example, PARAGON-HF 
[23], included patients with LVEF ≥ 45% and any wall thickness, and failed to show any benefit 
from sacubitril/valsartan in comparison with valsartan. One explanation could be that the 
population selected presented with different entities in the spectrum of HFpEF, and the 
pathophysiological mechanisms and the response to therapies might have been different in each 
form.  
In the present study, a very selected population of patients fulfilling criteria for HFpEF 
were included, with an LVEF ≥ 50% and with a maximal LV wall thickness of < 12 mm. In 
these concrete populations, the response to ACEI, ARB and beta-blockers was beneficial. The 
present hypothesis is that each form of HFpEF has a different profile, and a narrower approach 
to each entity integrating the big group of HFpEF could be useful for identifying the optimal 
therapy. 
Interestingly, it was found that high potassium levels at entry (defined as k > 5 mEq/L) 
was a negative prognostic factor for outcome, in terms of higher readmission for HF and 
mortality rates. The explanation for this may be that, on the one hand, hyperpotassemia may 
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indicate that the patient is not receiving enough non-potassium-sparing diuretics; and on the 
other hand, it can also reflect a certain degree of kidney failure and has been previously 
associated with increases in cardiovascular and HF-related events [29].  
On the other hand, patients taking clopidogrel had a higher risk of being readmitted for 
HF, which might be explained by more coronary artery disease and vascular disease, which 
might increase risk for these patients.  
This study has some limitations that may explain the failure to show a correlation between 
the presence of MGUS and clinical outcomes in HFpEF patients. In the first place, this is an 
observational and unicentric study, with possible selection bias that this study design implies 
and the limitation to extrapolate data to the general population. Second, sample size (n = 69) 
was not large and may have limited the ability to establish a relationship between HFpEF and 
MGUS. However, the findings reported herein may serve as a proof-of-concept, suggesting a 
need to search for MGUS in patients with HFpEF. Third, longer follow-up periods and larger 
studies are needed to truly assess the impact of MGUS on survival and hospitalization for HF. 
 
Conclusions 
In conclusion, the prevalence of MGUS in HFpEF patients with no LVH was roughly 
three-fold that of an age-matched general population; thus, it may be suggested that patients 
with MGUS be assessed for possible HF. Though a correlation was not found between MGUS 
and clinical outcomes for this population of HFpEF patients, longer follow-up studies are 
needed to fully rule out this possibility. The use of betablockers and ACEI or ARB reduced 
the combined endpoint of mortality and rehospitalization for HF in this HFpEF population, 
which may support the use of these treatments of these patients. Higher potassium levels may 
be a marker of poor prognosis in this population, and closer follow-up should be considered. 
Further studies are needed to clarify the state-of-the-art therapy for these patients, as their 
prevalence increases. 
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Table 1A. Basal characteristics (total population and combined endpoint of mortality and 
readmission for heart failure). 
Population 
description 
Total (n = 
69) 
No combined 
endpoint (n = 
35) 
Combined 
endpoint (n = 
34) 
P 
Age [years] 83 (77–86) 82 (77–87) 83 (79–86) 0.605 
Males  46.4 51.1 37.5 0.282 
Diabetic 30.4 31.1 29.2 0.867 
Smokers  32.4 31.8 33.3 0.898 
Dyslipidemia  56.5 60 50 0.426 
Arterial hypertension  81.2 84.4 75 0.343 
Atrial fibrillation  63.8 62.2 66.7 0.715 
Ischemic heart disease  14.5 15.6 12.5 0.732 
MGUS  13 15.6 8.3 0.403 
Medication at day 1 
ASA  24.6 24.4 25 0.959 
Anticoagulation  63.8 64.4 62.5 0.873 
Clopidogrel  4.4 2.2 8.3 0.276 
ACEIs or ARBs 50.7 60 33.3 0.038 
Beta-blockers  43.5 53.3 25 0.027 
CCB 17.4 15.6 20.8 0.583 
Thiazide diuretics  18.8 13.3 29.2 0.117 
Loop diuretics  73.9 75.6 70.8 0.427 
MRA  14.5 8.9 25 0.081 
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Digoxin  8.7 6.7 12.5 0.420 
Statins  52.2 57.8 41.7 0.204 
Antiarrhythmics  7.2 6.7 8.3 0.8 
Laboratory values 
Albumin levels [g/dL] 4.00 (3.75–4) 4.00 (3.5–4) 4.00 (4–4) 1 
Total protein count 
[g/dL] 
6.5 (6–7.07) 6.7 (6.1– 
7.125) 
6.3 (5.7–7.07) 0.370 
Creatinine [mg/dL] 1.1 (0.8–1.377) 1.1 (0.8–1.33) 1.08 (0.8–1.57) 0.446 
eGFR [mL/min] 56.9 (46.4–74) 57 (48–77.9) 56.4 (37.5–68.1) 0.205 
Glycaemia [mg/dL] 104 (88.5– 27) 105 (92–123) 101 (86.5–141) 0.855 
Hemoglobin [g/dL] 12.2 (11.1–
13.15) 
12.2 (11.3–13) 11.9 (10.9–13.5) 0.806 
Platelet count [n/mm3] 208 000 
(174000–
279500) 
215000 
(174000–
290500) 
192000 
(171250–
242250) 
0.453 
WBC count [n/mm3] 6930 (5770–
8975) 
7000 (6000–
9150) 
6425 (5700– 
8395) 
0.326 
Segmented neutrophils 
[%] 
67.5 (61.7–74) 67 (61–74) 67.9 (62–81) 0.469 
Sodium [mEq/L] 139 (136–141) 139 (136–142) 139 (135–141) 0.519 
Potassium [mEq/L] 4.2 (3.8–4.55) 4.2 (3.7–4.3) 4.2 (4–4.7) 0.225 
NT-proBNP [pg/mL] 1900 (1096–
2960) 
1600 (894–
2628) 
3140 (2200–
9990) 
0.121 
BNP [pg/mL] 368 (130–885) 218 (112–495) 595 (400.5–
1128) 
0.003 
Potassium > 5 mEq/L 10.1 4.4 20.8 0.049 
Natriuretic peptides 
over the median† 
59.6 51.2 81.3 0.047 
Echocardiographic values 
Ejection fraction 60 (55–60) 60 (55–60) 60 (51–63.7) 0.742 
LA (PLA) [mm] 41 (36–45) 41 (37–45) 41 (36–45) 0.354 
LA (AFC) [mm] 59 (53–63.5) 59 (55–63) 58 (50–65) 0.414 
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LA dilatation 88.4 86.7 91.7 0.54 
Diastolic dysfunction 
or non-evaluable 
98.6 97.3 100 0.282 
Values are median (interquartile range) or percentages. †Natriuretic peptides over the median were defined as 
NT-proBNP levels > 1900 pg/mL or BNP > 368 pg/mL. 
ACEIs — angiotensin converter enzyme inhibitors; AFC — apical four chamber; ARBs — angiotensin II 
receptor blockers; ASA — acetylsalicylic acid; BNP — B-type natriuretic peptide; CCB — calcium channel 
blockers; eGFR — estimated glomerular filtration rate; LA — left atrium; MGUS — monoclonal gammopathy 
uncertain significance; MRA — mineral corticoid receptor antagonists; NT-proBNP — N-terminal pro-BNP; 
PLA —parasternal long axis; WBC — white blood cell 
 
Table 1B. Basal characteristics (readmission for heart failure [HF] and mortality). 
Population 
description 
Readmission 
for HF (n = 18) 
No 
readmissio
n for HF (n 
= 51) 
P Mortality 
(n = 11) 
No 
mortality 
(n = 58) 
P 
Age [years] 83.5 (81.8–87.2) 81 (77–86) 0.108 82 (77–86) 83 (77–87) 0.693 
Males  33.3 51 0.201 36.4 48.3 0.470 
Diabetic 27.8 31.4 0.776 18.2 32.8 0.344 
Smokers  27.8 33.3 0.629 36.4 31 0.756 
Dyslipidemia  44.4 60.8 0.233 54.5 56.9 0.885 
Arterial 
hypertension  
77.8 82.4 0.670 63.6 84.5 0.117 
Atrial 
fibrillation  
72.2 60.8 0.388 54.5 65.5 0.49 
Ischemic heart 
disease  
5.6 17.6 0.237 18.2 13.8 0.706 
MGUS  5.6 15.7 0.295 9.1 13.8 0.674 
Medication at day 1     
ASA  16.7 27.5 0.366 27.3 24.1 0.825 
Anticoagulation  72.2 60.8 0.388 54.5 65.5 0.490 
Clopidogrel  11.1 2 0.15 9.1 3.4 0.426 
ACEIs or ARBs 38.9 54.9 0.246 27.3 55.2 0.102 
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Beta-blockers  22.2 51 0.041 18.2 48.3 0.082 
CCB  22.2 15.7 0.531 9.1 19 0.440 
Thiazide 
diuretics  
22.2 17.6 0.67 36.4 15.5 0.117 
Loop diuretics  66.7 76.5 0.275 81.8 72.4 0.691 
MRA  22.2 11.8 0.286 27.3 12.1 0.202 
Digoxin  16.7 5.9 0.18 0 10.3 0.999 
Statins  38.9 56.9 0.194 45.5 53.4 0.627 
Antiarrhythmics  11.1 5.9 0.469 0 8.6 0.999 
Laboratory values 
Albumin levels 
[g/dL] 
4 (4–4) 4.00 (3.5–4) 1 4 (4–4) 4 (3.75–4) 1 
Total protein 
count [g/dL] 
6.3 (5.6–7) 6.7 (6.1–
7.2) 
0.220 6.4 (5.7–
7.7) 
6.5 (6.05–
6.9) 
0.908 
Creatinine 
[mg/dL] 
1.05 (0.8–1.32) 1.1 (0.8–
1.37) 
0.967 1.19 (0.8–
1.7) 
1.07 (0.8–
1.3) 
0.321 
eGFR [mL/min] 56.9 (47–68.1) 56.9 (45–
76) 
0.481 51 (37–
68.1) 
57 (48–
74.5) 
0.235 
Glycaemia 
[mg/dL] 
95 (82.2–143) 107 (92–
124) 
0.280 97 (80–
122) 
104.5(91.7–
130.2) 
0.354 
Hemoglobin 
[g/dL]  
11.8(10.9– 3.6) 12.2 (11.2–
13.1) 
0.722 11. (10.9–
14) 
12.2(11.2–
13.1) 
0.426 
Platelet count 
[n/mm3] 
192000 
(168500–8750) 
215000 
(173000–
296000) 
0.328 185000 
(170000–
246000) 
213500 
(174500–
282750) 
0.566 
WBC count 
[n/mm3] 
6425 (4955–
7945) 
7000 
(5960–
9410) 
0.176 5900 
(5740–
9690) 
7000 
(5917–
8962) 
0.363 
Segmented 
neutrophils [%] 
67.9 (60.5–84.3) 67 (62–73) 0.448 67.1 
(61.3–73) 
67.9 (61.8–
75.5) 
0.87 
Sodium 
[mEq/L] 
139.5 (136–141) 139 (136–
141) 
0.896 137 (135–
140) 
136 (139–
141) 
0.361 
Potassium 
[mEq/L] 
4.3 (3.9– 4.9) 4.2 (3.7–
4.3) 
0.166 4.2 (4–4.6) 4.1 (3.7–
4.5) 
0.616 
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NT-proBNP 
[pg/mL] 
2350 (1271–
2980) 
1900 
(1074–
3310) 
0.748 6915 
(1681.5–
22897.5) 
1900 
(1074–
2635) 
0.113 
BNP [pg/mL] 595 (292–1000) 262 (1129–
730) 
0.147 522.5(338
–1464.5) 
281.5 
(129.75–
781.75) 
0.197 
Potassium > 5 
mEq/L 
22.2 5.9 0.064 9.1 10.3 0.9 
Natriuretic 
peptides over 
the median† 
75 55.6 0.231 71.4 58 0.5 
Echocardiographic values  
Ejection 
fraction 
60 (58.5–60) 60 (55–60) 0.305 60 (50–65) 60 (55–60) 0.993 
LA (PLA) [mm] 41.5 (36–46.7) 41 (36.2–
44.7) 
0.64 38(33–
42.5) 
42 (37–
45.5) 
0.207 
LA (AFC) 
[mm] 
59 (50.7–69.5) 59 (54–62) 0.633 57 (50–60) 60 (54.7–
65) 
0.083 
Left atrium 
dilatation 
94.4 86.3 0.369 81.8 89.7 0.463 
Diastolic 
dysfunction or 
non-evaluable 
100 98 0.355 100 98.3 0.205 
Values are median (interquartile range) or percentages. †Natriuretic peptides over the median were defined as 
NT-proBNP levels > 1900 pg/mL or BNP > 368 pg/mL. 
ACEIs — angiotensin converter enzyme inhibitors; AFC — apical four chamber; ARBs — angiotensin II 
receptor blockers; ASA — acetylsalicylic acid; BNP — B-type natriuretic peptide; CCB — calcium channel 
blockers; eGFR — estimated glomerular filtration rate; LA — left atrium; MGUS — monoclonal gammopathy 
uncertain significance; MRA — mineral corticoid receptor antagonists; NT-proBNP — N-terminal pro-BNP; 
PLA —parasternal long axis; WBC — white blood cell 
 
Table 2. Outcomes by group (presence or absence monoclonal gammopathy of uncertain 
significance [MGUS]) 
 MGUS (n = 9) No MGUS (n = 60) P 
Composite endpoint 2 (22.2%) 22 (36.7%) 0.403 
Admission for HF  1 (11.1%) 17 (28.3%) 0.295 
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Mortality 1 (11.1%) 10 (16.7%) 0.674 
Values are number of patients and percentages. HF — heart failure 
 
Table 3A. Multivariate Cox regression for combined endpoint (admission for heart failure 
and mortality) 
Variable  Hazard 
ratio  
95% 
confidence 
interval 
P 
(multivariate) 
ACEIs or ARBs 0.153 0.037–0.622 0.009 
Beta-blockers 0.192 0.05–0.736 0.016 
Potassium > 5 mEq/L 6.074 1.6–22.65 0.007 
ACEIs — angiotensin converter enzyme inhibitors; ARBs — angiotensin II receptor blockers 
 
Table 3B. Multivariate Cox regression for admission for heart failure. 
Variable  Hazard 
ratio  
95% 
confidence 
interval 
P 
(multivariate) 
ACEIs or ARBs 0.353 0.121–1.026 0.056 
Beta-blockers 0.272 0.087–0.851 0.025 
Clopidogrel 7.938 1.458–43.227 0.017 
ACEIs — angiotensin converter enzyme inhibitors; ARBs — angiotensin II receptor blockers 
 
Table 3C. Uni- and multivariate Cox regression for admission for mortality.  
Variable  Hazard 
ratio  
95% 
confidence 
interval 
P 
(multivariate) 
ACEIs or ARBs 0.275 0.073–1.041 0.057 
Beta-blockers 0.27 0.058–1.249 0.094 
ACEIs — angiotensin converter enzyme inhibitors; ARBs — angiotensin II receptor blockers 
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Figure 1. The recruiting and enrollment process; COPD — chronic obstructive pulmonary 
disease; DPLD — diffuse parenchymal lung disease; PTE — pulmonary thromboembolism. 
 
Figure 2. Kaplan-Meier curves comparing patients taking beta-blockers with patients not 
taking beta-blockers; A. Time to composite endpoint; B. Time to rehospitalization for heart 
failure; C. Time to death.  
 
Figure 3. Kaplan Meier curves comparing patients taking angiotensin converter enzyme 
inhibitors (ACEIs)/angiotensin II receptor blockers (ARBs) with patients not taking 
ACEI/ARB; A. Time to composite endpoint; B. Time to re-hospitalization for heart failure. 
 
Figure 4. Kaplan-Meier curves comparing patients with potassium levels > 5 mEq/L with 
patients with potassium levels < 5 mEq/L by the time to the composite clinical endpoint.  
 




